ClinicalTrials.gg
Active, not recruitingNCT03825835HiLoUpdated Oct 5, 2026

30% or 60% Oxygen at Birth to Improve Neurodevelopmental Outcomes in Very Low Birthweight Infants

An interventional study of 30% oxygen group and 60% oxygen group in Premature Infant, Respiratory Distress Syndrome in Premature Infant and Neurodevelopmental Outcome, sponsored by University of Alberta. Active, not recruiting at 14 sites in 2 countries. Open to participants aged 0 Minutes to 10 Minutes. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by University of Alberta · Not applicable, Interventional, and Prevention

How we know

Updated Oct 5, 2026Now Active, not recruitingNo longer in Spain+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,203
Allocation
Randomized
Ages
0 Minutes to 10 Minutes
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Premature Birth with a site in Canada — 26 open to participants now, 34 under way, 2 of them phase 3. Premature Birth · Canada.

Planned enrollment
9th of 106
1,203 · median 80
Started
2022
with 8 others
No phase
65 of 139
9 open now
Primary completion
2028-09
later than 27 of 33 live
Registered
87th of 139
by date
Lead sponsor
8 of 139
University of Alberta

Among the 139 studies in Premature Birth with a site in Canada, this one is the 9th largest by planned enrollment of the 106 interventional ones that give a count, is one of 9 that started in 2022, is one of 65 with no phase, reaches primary completion later than 27 of the 33 other live ones, and was the 87th registered.

Premature Birth

2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.

Browse Premature Birth studies →

Open to participants now

26 of the 139 studies in Premature Birth with a site in Canada are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.

This study: 0 Minutes to 10 Minutes · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Premature Birth with a site in Canada, or all of them as a file.
02

Study summary

Preterm birth, or birth before 37 weeks' gestation, is increasingly common, occurring in 8 percent of pregnancies in Canada. Preterm birth is associated with many health complications, particularly when the birth happens before 29 weeks' gestation. At this gestational age, the lungs are not fully developed and it is not uncommon for infants to have problems breathing at the time of birth. One complication that can arise is when an infant stops breathing and needs to be resuscitated. When preterm babies need to be resuscitated doctors must take special care because of the small infant size and the immaturity of the brain and lungs. Oxygen is used to resuscitate babies who need it, but unfortunately there is disagreement about the best oxygen concentration to use. Oxygen concentration is important because both too much and too little oxygen can cause brain injury. This research aims to fill this knowledge gap by participating in an international clinical trial to compare the effects of resuscitating babies less than 29 weeks' gestational age with either a low oxygen concentration or a high oxygen concentration. The oxygen concentrations have been selected using the best available knowledge.

This will be a cluster randomized trial where each participating hospital will be randomized to either 30 or 60 percent oxygen for the recruitment of 30 infants, and afterwards randomized to the other group for the recruitment of another 30 infants. After the trial, the investigator will determine whether the babies resuscitated with low oxygen or those resuscitated with high oxygen have better survival and long-term health outcomes. This research fills a critical knowledge gap in the care of extremely preterm babies and will impact their survival both here in Canada and internationally.

Read the detailed description

Purpose: Over the last 10 years, recommendations regarding the ideal level of oxygen for resuscitation in preterm infants have changed from 100 percent, down to low levels of oxygen (\<30 percent), up to moderate concentration (30-65 percent). In addition, in 2010, oxygen saturation targeting was recommended as standard of care and this contributed to a change in clinical practice as clinicians were more likely and comfortable to start resuscitation at either 21percent (room air) or titrated levels of oxygen such as 30-40 percent. When the guidelines were again revised in 2015, the International Liaison Committee on Resuscitation (ILCOR) acknowledged that a critical knowledge gap continued to exist for the resuscitation of the preterm infants \<37 weeks, highlighting the need to provide more concrete guidelines. This leaves clinicians in a challenging position. Despite the advances that have been achieved in perinatal and neonatal care, neonates are still vulnerable to the consequences of the oxidative effects from hyperoxia as well as the deleterious effects from hypoxia. A large, multi-centre international trial of sufficient sample size that is powered to look at safety outcomes such as mortality and adverse neurodevelopmental outcomes is required to provide the necessary evidenced to guide clinical practice with confidence.

Hypothesis: the null hypothesis for this study is that the incidence of mortality or abnormal neurodevelopmental outcomes at 24+/- 6 months corrected age will be no different by using either higher initial oxygen concentration of 60 percent compared to using lower initial oxygen concentration of 30 percent for resuscitation of preterm infants of 23 0/7- 28 6/7 weeks gestation.

Justification:

The use of supplementary oxygen may be crucial, but also potentially detrimental to premature infants at birth. High oxygen levels may lead to organ damage through oxidative stress, while low oxygen levels may lead to increased mortality. Excess oxygen exposure during the early post-birth period is associated with many complications and morbidities of preterm birth. Preterm infants have lower levels of anti-oxidant pathways consistent with their expected fetal environment of low oxygen exposure. Excess of oxygen free-radicals in infants intrinsically deficient in enzymatic antioxidants and non-enzymatic antioxidants may contribute to these morbidities. Pulmonary oxygen toxicity, through the generation of reactive oxygen and nitrogen species in excess of antioxidant defenses, is believed to be a major contributor to the development of bronchopulmonary dysplasia (BPD). Using lower oxygen concentrations at birth results in decreased oxidative stress markers and a decrease risk of developing BPD compared to higher oxygen concentrations. Other organs that may be damaged by such oxidative stress include kidneys, myocardium and the retina.

There is equally growing evidence that using lower oxygen concentrations will lead to lower oxygen saturation levels and bradycardia, which may lead to increased rates of mortality in this vulnerable group of infants. An individual patient analysis of clinical trials reported that 46% of preterm infants resuscitated with initial low oxygen concentration did not reach SpO2 of 80% at 5 min. This was associated with increased risk of major intraventricular hemorrhage (IVH), and an almost five times higher risk of death in this vulnerable group of infants. These data provide a warning note for the use of higher vs. lower initial oxygen concentration during delivery room resuscitation. As the investigator proceed in determining a safe range for resuscitation of ELBW/ELGA infants, it is highly likely that the optimum level of oxygen concentration is between the two extremes of 21 percent and 100 percent.

Objectives: To determine whether initial resuscitation of preterm neonates with 60 percent versus 30 percent oxygen results in better neurodevelopmental outcomes at 24+/- 6 months.

Research Method/Procedures: This will be a cluster crossover design, unmasked randomized controlled trial (RCT) comparing two oxygen concentrations at initiation of resuscitation. Infants will be placed on the resuscitation table with the initial steps of resuscitation carried out as per standard of care at each centre which usually follows current resuscitation guidelines. All centres will make every effort to establish adequate lung expansion using CPAP or positive pressure ventilation as needed. Enrolled infants will have a pulse oximeter sensor placed on the right arm in the first minute of life. Their resuscitation will be initiated with an oxygen concentration of 30 or 60 percent depending on the randomization sequence at the centre at the given time. Infants in the 30 percent group will remain in 30 percent oxygen until 5 min of age unless the infant's heart rate (HR) remains 100/min or less and does not show a tendency towards progressive increase before reaching 5 min of age or infant needs chest compression and/or epinephrine. No alteration in oxygen concentration will be made for an infant who is responding to resuscitation efforts with HR progressively increasing as minutes go by. At 5 min of age, the clinical team will assess oxygen saturation. If the saturation is less than 85 percent, oxygen should be increased by 10-20 percent every 60 sec to achieve saturations of 85 percent or greater or a saturation of 90-95 percent at 10 min of age. If saturations are greater than 95 percent at or before 5 min of age, oxygen should be decreased stepwise (every 60 sec) with an aim to maintain saturations of 85 percent or greater during 5-10 min of age or 90-95 percent at and beyond 10 min of age. The procedure for infants in the 60 percent group will be identical. The intervention duration for the trial will be the first 5 min after birth followed by initial monitoring/action for the next 5 min where titration in oxygen concentration will be made to achieve stability making a total of 10 min for study intervention. Titration of oxygen before 5 min after birth will only be made if the infant remains bradycardic (HR less than 100) and does not show a tendency towards a sustained increase in HR or if the oxygen saturation exceeds 95 percent. If the infant does not respond to ventilation with increasing HR in the first 5 min after birth, steps to ensure effective ventilation should be done before oxygen is titrated.

Plan for Data Analysis: Generalized linear mixed model with binary outcome and maximum likelihood estimate will be used to evaluate the effect of an oxygen concentration on the primary outcome (as a composite at 24+/- 6 months corrected age of all-cause mortality or the presence of a major neurodevelopmental outcome). To account for cluster crossover design of the study, effects of centers (clusters) and a period (oxygen concentration) within center will be considered random, and effects of a period (oxygen concentration) will be entered as a fixed effect. This hierarchical model allows for the correlation of patients within periods and within clusters. The model will be adjusted for gestational age and whether or not infant required mask ventilation as potential confounding variables. Similar generalized linear mixed models will be performed to evaluate the effect of group on secondary outcomes. In addition, three subgroup analysis will be performed: i) Gestational age will be categorized into 2 categories: 23+0- 25+6 vs. 26+0-28+6 weeks; ii) Breathing support will be categorized by infants supported only with CPAP vs. received mask ventilation; iii) Sex/Gender will be categorized into 2 categories: female vs. male. For subgroup analysis baseline characteristics will be compared using linear and generalized linear mixed models. Sensitivity analysis will be performed to analyze the missing data; however, a very low number of missing values are expected due to the design of the study.

03

Conditions studied

  • Premature Infant
  • Respiratory Distress Syndrome in Premature Infant
  • Neurodevelopmental Outcome

Browse trials for

Keywords

  • Delivery Room
  • Resuscitation
  • Premature Infant
  • Oxygen
04

Who can participate

Ages eligible
0 Minutes to 10 Minutes
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants born at 23 0/7 weeks to 28 6/7 weeks' gestational age who will receive full resuscitation and are without major congenital abnormalities

Exclusion criteria

Exclusion Criteria:

  • Infants who are outborn - initial resuscitation not performed at the study centre
  • Infants who are not born within the eligible gestational age range- this trial is specific to preterm infants
  • Infants who are born with a major congenital abnormality- congenital abnormalities may affect oxygenation or neurodevelopmental outcomes
  • Infants who will not receive full resuscitation at birth- these infants will not receive resuscitation
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
1,203 participants (estimated)

Study arms

  • Active comparator
    30% group

    Infants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age. Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed.

    Drug: 30% oxygen group

  • Experimental
    60% group

    Infants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age. Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed.

    Drug: 60% oxygen group

Interventions

  • DrugOxygenStudies of OxygenOxygen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Infants in the 30% oxygen group will remain in 30% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age. Intervention: Infants randomized to the 30% oxygen group will receive 30% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed.

  • DrugOxygenStudies of OxygenOxygen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Infants in the 60% oxygen group will remain in 60% oxygen (O2) until 5 min of age. At 5 min of age, the clinical team will assess oxygen saturation (SpO2). If SpO2 is \<85%, O2 should be increased by 10-20% every 60 sec to achieve SpO2 of 85% or greater or a SpO2 of 90-95% at 10 min of age. If SpO2 are greater than 95% at or before 5 min of age, O2 should be decreased stepwise (every 60 sec) with an aim to maintain SpO2 of 85% or greater during 5-10 min of age or 90-95% at and beyond 10 min of age. Intervention: Infants randomized to the 60% oxygen group will receive 60% oxygen at birth for the first 5 minutes. At 5 minutes oxygen can be adjusted as needed.

06

What researchers measure

Primary outcomes

  1. Number of participants with composite outcome of all-cause mortality or the presence of a major neurodevelopmental outcomes

    Defined as any one of the following: Mortality or (i) cerebral palsy with an inability to walk unassisted; (ii) major developmental delay involving cognition or language; or (iii) visual (cannot fixate/legally blind, or corrected acuity \< 6/60 in both eyes) or hearing impairment (requiring a hearing aid or cochlear implants).

    Time frame: 24+/- 6 months corrected age

Secondary outcomes

  1. Number of intubation in the delivery room

    Number of infants intubated in the delivery room

    Time frame: first 15 minutes after birth

  2. Death in the Neonatal Intensive Care Unit

    Number of infants died after admission in the Neonatal Intensive Care Unit

    Time frame: During admission in the Neonatal Intensive Care Unit; no exact time frame can be given as this can happen after 1 day, 1 week, 1 months or up to 2-3 month. again deepening on gestational age and policy for transferring infants at participating centres.

  3. Number of participants who died in the delivery room

    Number of infants died in the delivery room during resuscitation

    Time frame: During resuscitation in the delivery room; for lay people: this time frame might be 10min or 1-3 hours, depending on the approaching each participating hospital

  4. Number of participants with severe brain injury on cranial ultrasound

    Severe grade 3 and 4 intraventricular or intraparenchymal hemorrhage according to Papile \[44\], periventricular leukomalacia, or ventriculomegaly based on neuroimaging studies (timing and frequency of imaging based on local site practices)

    Time frame: During NICU admission (up to 6 months)

  5. Number of participants with severe retinopathy of prematurity stage 3 or higher

    As defined in the International Classification of ROP and/or ROP treated with laser, cryo-therapy, or intraocular injection therapy

    Time frame: During NICU admission (up to 6 months)

  6. Number of participants with necrotizing enterocolitis

    Defined as modified Bell's criteria stage 2 or greater

    Time frame: During NICU admission (up to 6 months)

  7. Number of participants with hearing loss

    Audiometry will be performed to assess the presence or absence of severe hearing loss.

    Time frame: 24+/- 6 months of age

  8. Number of participants with blindness

    Blindness will be defined as a corrected visual acuity of \<20/200.

    Time frame: 24+/- 6 months of age

  9. Number of participants with mortality

    All cause mortality from birth until follow-up at 24+/- 6 months of age

    Time frame: From birth up to 24+/- 6 months of age

  10. Number of participants with cerebral palsy with an inability to walk unassisted

    Defined as cerebral palsy with an inability to walk unassisted

    Time frame: 24+/- 6 months of age

  11. Number of participants with bronchopulmonary dysplasia at 36 weeks corrected age

    Defined as receiving any supplemental oxygen or any form of respiratory support (including invasive mechanical ventilation, non-invasive ventilation with continuous positive airway pressure, nasal intermittent positive pressure ventilation, or high-flow nasal cannula)

    Time frame: At 36 weeks corrected age

  12. Number of participants with bronchopulmonary dysplasia at 40 weeks corrected age

    Defined as receiving any supplemental oxygen or any form of respiratory support (including invasive mechanical ventilation, non-invasive ventilation with continuous positive airway pressure, nasal intermittent positive pressure ventilation, or high-flow nasal cannula)

    Time frame: At 40 weeks corrected age

  13. Total duration of mechanical ventilation via an endotracheal tube in days

    Days of receiving mechanical ventilation

    Time frame: Days during NICU Admission (up to 6 months)

  14. Number of participants discharged home on oxygen

    Infants who are discharged home with oxygen

    Time frame: At NICU Discharge

  15. Duration of any positive pressure respiratory support in days

    Defined as (invasive mechanical ventilation, non-invasive ventilation with continuous positive airway pres- sure, nasal intermittent positive pressure ventila- tion, or non-invasive neural assist ventilation or non-invasive high frequency ventilation, or high- flow nasal canula) in days

    Time frame: Days during NICU Admission (up to 6 months)

  16. Duration of supplemental oxygen in days

    Number of days the infant receives any supplemental oxygen

    Time frame: Days during NICU Admission (up to 6 months)

  17. Length of hospital stay in days

    number of days the infants I admitted in the nICU

    Time frame: Days from birth to discharge (up to 6 months)

  18. Z-scores for weight, length, head circumference, and body mass index

    we will calculate Z-scores for weight, length, head circumference, and body mass index

    Time frame: At 36 weeks' corrected age

  19. Differences in oxygen saturation in percentage

    we will compare the oxygen saturation in both groups

    Time frame: At 3, 5, and 10 min of age after birth

07

Study locations

14 sites
08

References and documents

Publications

  • Schmolzer GM, Asztalos EV, Beltempo M, Boix H, Dempsey E, El-Naggar W, Finer NN, Hudson JA, Mukerji A, Law BHY, Yaskina M, Shah PS, Sheta A, Soraisham A, Tarnow-Mordi W, Vento M; behalf of the HiLo trial collaborators. Does the use of higher versus lower oxygen concentration improve neurodevelopmental outcomes at 18-24 months in very low birthweight infants? Trials. 2024 Apr 4;25(1):237. doi: 10.1186/s13063-024-08080-2. PubMed 38576007 ↗

Individual participant data

Plan to share: Yes — The data will be included in a prospectively planned IPD, which is called PROMOTION Other researchers can email the PI for more information at georg.schmoelzer@me.com Study protocol: https://link.springer.com/article/10.1186/s13063-024-08080-2

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: after the publication of the primary results indefinitely

Access criteria: Other researchers can email the PI for more information at georg.schmoelzer@me.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Sep 2028, 75 months after the start.

Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 75 months is above that.

Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.

Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2029 → Sep 2028, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2019
First posted
Jan 31, 2019
StartActual
Jun 27, 2022
Primary completionEst.
Sep 30, 2028was Sep 2029
CompletionEst.
Dec 30, 2029
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 5, 2026
Sites
7 sites removed; no longer in Spain
Show 7 removed
  • Queen's University · Kingston, Canada
  • Hospital Germans Tries i Pujol · Barcelona, Spain
  • Hospital Universitario Dexeus · Barcelona, Spain
  • Hospital de la Arrixaca · El Palmar, Spain
  • Hospital Las Palmas · Las Palmas de Gran Canaria, Spain
  • Hospital de Asturias · Oviedo, Spain
  • Hospital Universitario Materno Infantil Miguel Servet · Zaragoza, Spain
Oct 5, 2026
Primary completion
Sep 30, 2029→Sep 30, 2028
Oct 5, 2026
Enrollment
1200→1203
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Recruiting→Active, not recruiting
    7 sites removed; no longer in Spain
    Show 7 removed
    • Queen's University · Kingston, Canada
    • Hospital Germans Tries i Pujol · Barcelona, Spain
    • Hospital Universitario Dexeus · Barcelona, Spain
    • Hospital de la Arrixaca · El Palmar, Spain
    • Hospital Las Palmas · Las Palmas de Gran Canaria, Spain
    • Hospital de Asturias · Oviedo, Spain
    • Hospital Universitario Materno Infantil Miguel Servet · Zaragoza, Spain
    Primary completion Sep 30, 2029→Sep 30, 2028
    Enrollment 1200→1203
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03825835
Responsible party
Sponsor
First posted
Jan 31, 2019
Start date
Jun 27, 2022
Primary completion
Sep 30, 2028 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

Georg Schmolzer, MD, PhD
principal investigator · University of Alberta

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxygen

Start the discussion